Evidence map›Paper›PMID 40162434›Full record

ArticleJournal of translational autoimmunity2025

Pediatric autoimmune diseases in the light of COVID-19 pandemic, A retrospective observational big data study.

Rim Kasem Ali Sliman, Hilla Cohen, Shereen Shehadeh, Reut Batcir, Yigal Elenberg Alter, Keren Cohen, Ilana Koren, Inbal Halabi, Hussein Sliman, Mohamad Hamad Saied

Abstract read
In one paragraph

Article in Journal of translational autoimmunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Rim Kasem Ali SlimanTechnion Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa 3109601, Israel.
Hilla CohenClalit Health Care Organization, Carmel Medical Center, Haifa, Israel.
Shereen ShehadehTechnion Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa 3109601, Israel.
Reut BatcirTechnion Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa 3109601, Israel.
Yigal Elenberg AlterTechnion Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa 3109601, Israel.
Keren CohenTechnion Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa 3109601, Israel.
Ilana KorenTechnion Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa 3109601, Israel.
Inbal HalabiTechnion Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa 3109601, Israel.
Hussein SlimanTechnion Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa 3109601, Israel.
Mohamad Hamad SaiedTechnion Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa 3109601, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The COVID-19 pandemic has raised concerns about potential links between SARS-CoV-2 infection and autoimmune diseases. This study investigated changes in the incidence rate (IR) of autoimmune diseases among children following the pandemic's onset. Methods: A retrospective cross-sectional study analyzed data from Clalit Health Services, Israel's largest healthcare provider, examining the IR of different autoimmune diseases in children aged 0-18. The study compared pre-pandemic (2019) with pandemic/post-pandemic periods (2020-2023), encompassing a cohort of over 1.5 million children. Results: Significant IR increases were observed across multiple autoimmune diseases. Rheumatic diseases (Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Henoch Schoenlein Purpura (HSP)) showed consistent increases, with HSP demonstrating the most pronounced trend. Endocrine disorders exhibited diverse patterns, with autoimmune thyroid diseases and Type 1 diabetes showing overall increases, while diabetic ketoacidosis exhibited an initial spike followed by a decline. Gastrointestinal diseases displayed heterogeneous patterns; Celiac disease and Ulcerative colitis showed general increases, Crohn's disease showed a downward trend, and autoimmune hepatitis exhibited an initial significant decrease followed by a significant increase. Dermatological conditions, including Psoriasis and Vitiligo, demonstrated consistent elevations throughout 2020-2023. Immune Thrombocytopenia Purpura showed initial decreases followed by significant increases in 2022-2023. Conclusions: This comprehensive analysis reveals significant changes in pediatric autoimmune disease incidence following the COVID-19 pandemic, suggesting potential associations between SARS-CoV-2 infection and autoimmune dysregulation. The diverse patterns observed across different conditions highlight the complex interplay between viral infection and autoimmunity, emphasizing the need for continued surveillance and investigation of long-term immunological consequences of COVID-19 in pediatric populations.

Indexed as

Autoimmune diseasesChildrenCOVID-19EpidemiologyIncidence rateSARS-CoV-2

Identifiers

PMID40162434
PMCPMC11951201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.